CANbridge Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

CANbridge Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 6.8% bzw. 35.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 6.8% pro Jahr wachsen soll.

Wichtige Informationen

6.8%

Wachstumsrate der Gewinne

6.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	35.1%
Wachstumsrate der Einnahmen	35.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	23 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Apr 23

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

May 05

Gewinn- und Umsatzwachstumsprognosen

SEHK:1228 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	300	-284	N/A	N/A	1
12/31/2025	150	-324	N/A	N/A	1
12/31/2024	130	-250	N/A	N/A	1
12/31/2023	103	-379	-319	-278	N/A
9/30/2023	95	-416	-316	-291	N/A
6/30/2023	87	-453	-314	-304	N/A
3/31/2023	83	-468	-305	-292	N/A
12/31/2022	79	-483	-296	-281	N/A
9/30/2022	66	-733	-340	-327	N/A
6/30/2022	54	-982	-384	-373	N/A
3/31/2022	42	-1,089	-599	-591	N/A
12/31/2021	31	-1,077	-461	-587	N/A
9/30/2021	27	-1,055	-391	-515	N/A
6/30/2021	22	-1,034	-321	-443	N/A
3/31/2021	18	-828	-218	-196	N/A
12/31/2020	12	-846	-305	-152	N/A
12/31/2019	1	-218	-169	-126	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 1228 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 1228 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 1228 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 1228Die Einnahmen des Unternehmens (35.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.9% pro Jahr).

Hohe Wachstumseinnahmen: 1228Die Einnahmen des Unternehmens (35.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 1228 in 3 Jahren voraussichtlich hoch sein wird

CANbridge Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 23%

Price target decreased by 21% to HK$7.00

Consensus EPS estimates upgraded to CN¥0.59 loss

Price target decreased by 82% to HK$1.70

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus EPS estimates upgraded to CN¥1.05 loss

Recent updates

Consensus EPS estimates fall by 23%

Price target decreased by 21% to HK$7.00

Consensus EPS estimates upgraded to CN¥0.59 loss

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress

CANbridge Announces NDA Acceptance of CAN108 (???®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration

Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China

Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Algs)

First half 2023 earnings released: CN¥0.51 loss per share (vs CN¥0.59 loss in 1H 2022)

CANbridge Pharmaceuticals Inc. to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 82% to HK$1.70

Consensus revenue estimates decrease by 22%, EPS upgraded

New minor risk - Share price stability

CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart (CAN106) in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Consensus EPS estimates upgraded to CN¥1.05 loss

CANbridge Pharmaceuticals, Inc. Announces Marketing Approval of CAN108 (LIVMARLI) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

CANbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in China Region of the Global LIVMARLI(R) (CAN108) EMBARK Phase 2 Study in Biliary Atresia

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

High number of new and inexperienced directors

First half 2022 earnings released: CN¥0.59 loss per share (vs CN¥46.79 loss in 1H 2021)

CANbridge Pharmaceuticals Inc. to Report First Half, 2022 Results on Aug 24, 2022

Canbridge Pharmaceuticals Inc. Announces First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Canbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Announces Results from its CAN106 Phase 1 Trial

CANbridge Pharmaceuticals Inc. Appoints Pauline Li as Senior Vice President of Clinical Development and Operations

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. Announces Executive Changes

CANbridge Pharmaceuticals Inc. Announces First Patient Has Been Dosed in the Can106 Phase 1B/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria in China

Canbridge Pharmaceuticals Inc. Announces Approval of Can108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone

CANbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Reports Positive Top-Line Can106 Phase 1 Data

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals Inc. has completed an IPO in the amount of HKD 685.13718 million.

Less than half of directors are independent

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken